Novo Nordisk: extends collaboration with Valo Health

(CercleFinance.com) - Novo Nordisk and Valo Health announce an extension of their collaboration to discover and develop innovative treatments for obesity, type 2 diabetes and cardiovascular disease, leveraging Valo's artificial intelligence and human data.


The initial agreement, signed in September 2023, included up to 11 therapeutic programs and potential payments of $2.7 billion.

The expanded agreement now includes up to 20 programs, with potential payments of $4.6 billion, an initial investment of $190 million, and a strengthened focus on obesity and diabetes.

Both companies will use Valo's Opal platform and their respective expertise to identify promising therapeutic targets and develop treatments based on human-centered models.

Copyright (c) 2025 CercleFinance.com. All rights reserved.